99¢ of every dollar received goes to fund cancer research
The Gateway’s research mission is to support patient-centered research that improves cancer treatment outcomes and restores the cancer patients’ quality of life.
Since its inception over 20 years ago, The Gateway has funded over 103 innovative cancer research clinical trials. New trials are added throughout the year.
The Gateway supports innovative clinical research in conventional as well as complementary therapies. Read More »
Blood Cancer: |
Trial of Immune Suppressive Medications for Graft vs. Host Disease Following Stem Cell TransplantsJoseph Pidala Acute graft vs. hose disease (acute GVHD) is a major complication of stem cell transplantation (HCT), which can lead to significant morbidity, mortality and impaired quality ... |
| Moffitt Cancer Center | |
Active Trial |
Accepting new patients? Yes More Information » |
Brain Cancer |
Phase I/II Trial of the IGF-1R Inhibitor for Patients with Recurrent Malignant Astrocytoma Robert Aiken, MDMore effective therapies for treatment of malignant brain cancers are needed. The most common and lethal of these tumors are anaplastic astrocytoma and glioblastomas. M... |
| Rush University Medical Center | |
Active Trial |
Accepting new patients? Yes More Information » |
Breast Cancer |
Phase II Trial - Effects of Herceptin on Survival in Breast Cancer PatientsRebecca Aft, MDMetastasis is the most significant contributor to mortality in cancer patients. In breast cancer and other cancers, bone marrow is thought to serve as a reservoir for disseminated ... |
| Washington University, St. Louis, MO | |
Active Trial |
Accepting new patients? No More Information » |
Pediatric Cancer: |
New Epigenetic Approaches to Leukemia Therapy for Children Weili Sun, MD AML (acute myeloid leukemia) is the second most common leukemia in children; long term survival has improved to nearly approximately 60% over the last 50 years. However, trea... |
| Children's Hospital of Los Angeles | |
Active Trial |
Accepting new patients? No More Information » |
Pediatric Cancer: |
Prevention of Nephrotoxicity in Pediatric Osteosarcoma Frank Balis, MDOsteosarcoma is a malignant sarcoma of the bone that afflicts children, adolescents and young adults in the prime of life. Standard therapy includes dose intensive chemotherapy and... |
| Children’s Hospital Philadelphia, Philadelphia, PA | |
Active Trial |
Accepting new patients? No More Information » |
Quality of Life Cancer Study: |
Phase II: Cognitive Impairment in Women with Breast Cancer: The COGNUTRIN TrialNagi Kumar, M.D.This is an innovative strategy to address the patient cognitive problem. This is a real problem and one of the first attempts to deal with cognitive impairment syndrome. This is a ... |
| Moffitt Cancer Center | |
Active Trial |
Accepting new patients? No More Information » |
Skin Cancer: Melanoma: |
Personalized Medicine for BRAF wilde-type Cancer Patricia LoRusso, DO and Jeffrey Trent, PhD Patients with metastatic melanoma have a dismal prognosis with a median survival rates of about six months. Recently developed therapies demonstrated clinical efficacy in patients ... |
| Karmanos Cancer Center & TGen | |
Active Trial |
Accepting new patients? No More Information » |
Advanced Malignancies |
Study of Water Soluable Curcumin in Advanced MalignanciesSiqing Fu, MD & Razelle Kurzrock, MDThe goal of this clinical research study is to find the highest tolerable doses of surface-controlled water dispersible curcumin that can be given to patients with advanced cancer.... |
| MD Anderson Cancer Center, Houston, TX | |
Active Trial |
Accepting new patients? No More Information » |
Anal Cancer |
Phase II Study for Treatment of Anal HSIL Cancer Misha Cohen, OMDThis study aims to demonstrate that a new noninvasive Chinese herbal topical ointment, AIJP, will treat precancerous anal lesions in order to prevent their progression to anal canc... |
| University of California, San Francisco | |
Active Trial |
Accepting new patients? No More Information » |
Blood Cancer: |
Phase II Study of Early Treatment Intervention for Chronic Lymphocytic Leukemia (CLL)Clive Zent, MDChronic Lymphocytic Leukemia (CLL) is a common blood cancer that is rarely cured and is eventually fatal in most patients. The Mayo researchers found that early intervention with n... |
| Mayo Clinic | |
Active Trial |
Accepting new patients? Yes More Information » |
CANCER FACTS:
1,500 American people died today from cancer.
1,500 more will die tomorrow and the next day and the next...
Demanding it all!
Funding innovative cancer research for
Treatments. Cures. Life.